| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Axsome Therapeutics, Inc. (AXSM) has 9 insiders with recent SEC Form 4 filings, including 14 buys and 6 sells. AXSM is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| Dir | 58.4K | $14.11M | -572 | |
| Dir | 30.4K | $7.34M | -12,180 | |
| CEO | 24.1K | $5.82M | - | |
| Other | 23.7K | $5.73M | - | |
| Dir | 11.4K | $2.76M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Apr 1, 2024 | Jacobson Mark L. | Chief Operating Officer | Sale+OE | 24,662 | $77.24 | $1,904,942.20 | -100% | +5.2% | +45.0% | |
| Mar 15, 2024 | Jeffs Roger66 | Director | Sale+OE | 32,323 | $69.84 | $2,257,449.25 | -8.2% | -4.0% | +61.4% | |
| Sep 15, 2023 | Coleman Mark | Director | Sale+OE | 29,588 | $75.18 | $2,224,430.37 | -6.5% | -2.6% | +24.5% | |
| Nov 19, 2021 | Jeffs Roger66 | Director | Buy | 3,950 | $37.30 | $147,350.01 | +3.4% | -15.1% | +56.9% | |
| Nov 18, 2021 | Pizzie Nick50 | Chief Financial Officer | Buy | 955 | $35.26 | $33,676.03 | +2.3% | -11.2% | +57.8% | |
| Nov 18, 2021 | Coleman Mark | Director | Buy | 1,430 | $35.09 | $50,180.73 | +0.2% | -11.2% | +57.8% | |
| Nov 17, 2021 | Saad Mark E50 | Director | Buy | 3,300 | $34.52 | $113,921.70 | +47.1% | -2.3% | +54.2% | |
| May 12, 2021 | Coleman Mark | Director | Buy | 500 | $58.15 | $29,075.00 | +0.1% | -58.3% | -55.6% | |
| Jun 29, 2020 | Coleman Mark | Director | Buy | 650 | $78.50 | $51,025.00 | +0.2% | - | - | |
| Jun 29, 2020 | Pizzie Nick50 | Chief Financial Officer | Buy | 777 | $76.64 | $59,549.28 | +1.9% | - | - |